Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments: Life Science related Specialty Chemicals and Other Specialty Chemicals. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates and key starting materials for active pharmaceutical ingredients. It provides other specialty chemicals used in various end-user segments, including specialty pigments, specialty dyes, and polymer additives. The company was incorporated in 1984 and is headquartered in Surat, India.
Revenue projections:
Revenue projections for ANURAS ANURAS's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.
Financial Ratios:
currentRatio
1.423000
forwardPE
51.147984
debtToEquity
44.566000
earningsGrowth
0.447000
revenueGrowth
0.247000
grossMargins
0.579330
operatingMargins
0.227520
trailingEps
8.560000
forwardEps
21.980000
ANURAS's current ratio 1.423, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, ANURAS can comfortably meet its immediate liabilities, reflecting a healthy financial standing. With ANURAS's forward PE being too high, further price appreciation may be limited, and a correction could occur. This valuation metric signals potential overvaluation, and investors should analyze it carefully along with other fundamentals to make informed decisions. Positive earnings and revenue growth for Anupam Rasayan India Ltd suggest that the company is expected to grow its business. This trend reflects strong financial performance, with continued profitability and sales increases indicating a bright outlook for future expansion. ANURAS's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance. With a forward EPS greater than its trailing EPS, ANURAS is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.
Price projections:
Price projections for ANURAS Price projections for ANURAS have been gradually lowered, signaling reduced optimism among analysts. This downward adjustment suggests that the company may face challenges in meeting previous growth expectations.
ANURAS's stock price has already exceeded the higher end of analysts' projections. With little room left for additional increases, this situation suggests that investors should be cautious as the stock may face challenges in maintaining its current valuation.
Recommendation changes over time:
Recommendations trend for ANURAS
The recent sell bias from analysts on ANURAS suggests investors should be cautious. However, it's a good idea to base decisions on a broader range of market indicators to gain a more complete and accurate view of the stock's potential performance in the near term.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
An in-depth examination of the factors contributing to the U.S. dollar's multi-year...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.